<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684680</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/3oo/6/19</org_study_id>
    <nct_id>NCT04684680</nct_id>
  </id_info>
  <brief_title>The Role of Zamzam Water in Idiopathic Oligohydramnios</brief_title>
  <official_title>Effect of Zamzam Water on Amniotic Fluid Index, in Oligohydramnios : a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of drinking zamzam water versus tap water&#xD;
      in increasing the AF index in women with oligohydramnios.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oligohydramnios refers to decrease in amniotic fluid and it is defined as a deepest fluid&#xD;
      pocket of less than 2 cm or an amniotic fluid index of 5 cm or less. Oligohydramnios&#xD;
      complicates 0.5% to 8% of pregnancies, and 12 % if postdates When it occurs in first half of&#xD;
      pregnancy it is associated with birth defects while in second half it causes poor fetal&#xD;
      growth, malpresentations , FHR decelerations , MAS , Fetal suicidal syndrome and increases&#xD;
      cesarean section and management and prognosis depend on gestational age&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open label randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label randomized controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>amniotic fluid index</measure>
    <time_frame>10 weeks</time_frame>
    <description>the change of the amniotic fluid volume</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Oligohydramnios</condition>
  <arm_group>
    <arm_group_label>zamzam water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tap water</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive the normal need of daily requirement of water (2.5 liter) in form of tap water</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>zamzam water</intervention_name>
    <description>will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term</description>
    <arm_group_label>zamzam water</arm_group_label>
    <other_name>study group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>tap water</intervention_name>
    <description>will receive the normal need of daily requirement of water (2.5 liter) in form of tap water</description>
    <arm_group_label>tap water</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pregnant female with idiopathic oligohydramnios&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with medical disorder&#xD;
&#xD;
          -  congenital anomalies&#xD;
&#xD;
          -  premature rupture of membrane&#xD;
&#xD;
          -  Patient refuse to participate&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant female with idiopathic oligohydramnios</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>nahla w shady, md</last_name>
    <role>Study Chair</role>
    <affiliation>Aswan universirty</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hany f Sallam, md</last_name>
    <phone>+201022336052</phone>
    <phone_ext>002</phone_ext>
    <email>hanygyne@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>nahla w shady, md</last_name>
    <phone>+201022336052</phone>
    <phone_ext>002</phone_ext>
    <email>nahlagyn@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aswan University Hospital</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hany F Sallam, MD</last_name>
      <phone>0122336052</phone>
      <phone_ext>002</phone_ext>
      <email>hany.farouk@aswu.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Nahla W Shady, MD</last_name>
      <phone>01092440504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 5, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>A Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oligohydramnios</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

